Immunotherapy for Ovarian Cancer

Justin M. Drerup, Yang Liu, Alvaro S. Padron, Kruthi Murthy, Vincent Hurez, Bin Zhang, Tyler J. Curiel*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


All work referenced herein relates to treatment of epithelial ovarian carcinomas, as their treatment differs from ovarian germ cell cancers and other rare ovarian cancers, the treatments of which are addressed elsewhere. Fallopian tube cancers and primary peritoneal adenocarcinomatosis are also generally treated as epithelial ovarian cancers. The standard of care initial treatment of advanced stage epithelial ovarian cancer is optimal debulking surgery as feasible plus chemotherapy with a platinum plus a taxane agent. If this front-line approach fails, as it too often the case, several FDA-approved agents are available for salvage therapy. However, because no second-line therapy for advanced-stage epithelial ovarian cancer is typically curative, we prefer referral to clinical trials as logistically feasible, even if it means referring patients outside our system. Immune therapy has a sound theoretical basis for treating carcinomas generally, and for treating ovarian cancer in particular. Advances in understanding the immunopathogenic basis of ovarian cancer, and the immunopathologic basis for prior failures of immunotherapy for it and other carcinomas promises to afford novel treatment approaches with potential for significant efficacy, and reduced toxicities compared with cytotoxic agents. Thus, referral to early phase immunotherapy trials for ovarian cancer patients that fail conventional treatment merits consideration.

Original languageEnglish (US)
Pages (from-to)1-20
Number of pages20
JournalCurrent treatment options in oncology
Issue number1
StatePublished - Jan 2015


  • Adoptive immunotherapy
  • CAR T cell
  • Cancer vaccine
  • Early phase clinical trials
  • Immune therapy
  • Monoclonal antibody
  • Oncolytic virus
  • Ovarian cancer
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology


Dive into the research topics of 'Immunotherapy for Ovarian Cancer'. Together they form a unique fingerprint.

Cite this